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Introduction
Polyglutamine diseases are inherited neurodegenerative diseases 
caused by the expansion of the polyglutamine tract (Ross, 1997; 
Orr, 2001). Expansion of polyglutamine repeats alters the confor-
mation or results in the misfolding of the disease-associated pro-
tein, thereby conferring a toxic gain of function that is selectively 
deleterious to neurons (Sato et al., 1999; Yoshizawa et al., 2000). 
Nuclear inclusions (NIs) with ubiquitination formed by the dis-
ease protein are a common pathological feature of polyglutamine 
diseases. Indeed, NIs have been observed in at least six poly-
glutamine diseases and many transgenic animal models and thus 
represent a common hallmark of polyglutamine diseases. Nuclear 
translocation of expanded polyglutamine protein (polyQ) was 
promoted effi   ciently in neuronal cells, suggesting that some 
neuronal factors containing a nuclear localization signal (NLS) 
may regulate the nuclear translocation of polyQ. Furthermore, 
polyQ nuclear aggregates have recently been demonstrated to in-
teract with and alter the nuclear structures of the promyelocytic 
leukemia protein (PML), a major component of nuclear bodies 
(Takahashi et al., 2003). We identifi  ed a novel guanosine tri-
phosphatase (GTPase), CRAG, which associated with PML and 
formed NIs in response to various stresses. We report that CRAG 
is involved in the mechanisms underlying nuclear translocation, 
ubiquitination, and inclusion body formation of polyQ.
Results and discussion
By screening for signaling targets of repulsive axon guidance 
factors, semaphorins (described in Materials and methods), 
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P
olyglutamine diseases are inherited neurodegener-
ative diseases caused by the expanded polygluta-
mine proteins (polyQs). We have identiﬁ  ed a novel 
guanosine triphosphatase (GTPase) named CRAG that 
contains a nuclear localization signal (NLS) sequence and 
forms nuclear inclusions in response to stress. After ultra-
violet irradiation, CRAG interacted with and induced an 
enlarged ring-like structure of promyelocytic leukemia 
protein (PML) body in a GTPase-dependent manner. Reac-
tive oxygen species (ROS) generated by polyQ accumula-
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tion triggered the association of CRAG with polyQ and 
the nuclear translocation of the CRAG–polyQ complex. 
Furthermore, CRAG promoted the degradation of polyQ 
at PML/CRAG bodies through the ubiquitin–proteasome 
pathway. CRAG knockdown by small interfering RNA in 
neuronal cells consistently blocked the nuclear transloca-
tion of polyQ and enhanced polyQ-mediated cell death. 
We propose that CRAG is a modulator of PML function 
and dynamics in ROS signaling and is protectively in-
volved in the pathogenesis of polyglutamine diseases.JCB • VOLUME 172 • NUMBER 4 • 2006  498
we identifi  ed a novel GTPase and named it CRAG, after col-
lapsin response mediator protein (CRMP)–associated molecule 
(CRAM [CRMP-5])–associated GTPase. The full-length CRAG 
cDNA presents an open reading frame of 369 amino acid resi-
dues containing a glutamine-rich domain at the NH2 terminus, a 
Ras homology domain in the middle, and an NLS at the COOH 
terminus (Fig. 1 a). Fig. 1 b indicates a comparison of structure 
between CRAG and other related GTPase proteins. The amino 
acid sequence of CRAG shows 95% identity with centaurin-γ3 
and 43% identity with the nuclear GTPase phosphatidylinositol 
3-kinase enhancer, short isoform (alignment is not depicted; Ye 
et al., 2000). Analysis of human genomic databases suggests that 
CRAG may be an alternative splicing variant of centaurin-γ3.
Northern blot analysis indicated that the CRAG gene was domi-
nantly expressed in brain and slightly in heart (Fig. 1 c). A band 
higher than CRAG that is present in various tissues may be 
 centaurin-γ3. Immunohistochemical analysis revealed a diffuse 
cytoplasmic distribution of CRAG in rat hippocampal neurons at 
rest (Fig. 1 d, top). Upon UV irradiation, an NI formed of CRAG 
was detected at 10 min (Fig. 1 d). These NIs exhibited a dough-
nut shape under the large-scale microscopic analysis (Fig. S1 A, 
available at http://www.jcb.org/cgi/content/full/jcb.200505079/
DC1). This phenomenon was reproduced in UV-  stimulated 
HeLa cells expressing HA-tagged CRAG (HA-CRAG) wild 
type (WT) or GTPase-defi  cient mutants (S114N; Fig. 1 e). In con-
trast, NLS-disrupted mutants of CRAG (KR342-343EE within 
the NLS motif) formed inclusions but were cytosolic even 
after UV stimulation. These results demonstrated that NLS, but 
not GTPase activity, was required for nuclear translocation and 
NI formation by CRAG.
We found that GFP fused to the NH2 terminus of CRAG 
WT or GTPase mutants spontaneously translocated to the nu-
cleus and formed NI without any stimulation. The absence of 
nuclear localization of NLS-disrupted mutants of GFP-CRAG 
Figure 1.  NI body formation of CRAG by 
  response to UV irradiation. (a) Amino acid se-
quence of CRAG. CRAG contains a Q-rich do-
main (dots), a Ras homology domain (blue), 
and an NLS sequence (red). (b) Comparison of 
CRAG with the related GTPase proteins cen-
taurin-γ3 and phosphatidylinositol 3-kinase 
  enhancer, short isoform. A, ankyrin repeat; P, 
proline-rich domain; PH, pleckstrin homology 
domain. (c) Northern blot analysis of CRAG in 
mouse tissues. The arrowhead indicates the 
position of CRAG mRNA. (d) NIs of CRAG in 
UV-irradiated hippocampal neurons. Cells 
were stimulated with or without a pulse of UV 
irradiation at 100 J/m
2 and after 10 min ﬁ  xed 
and immunostained with anti-CRAG antibody 
(green) and Hoechst 33258 (blue). The arrow-
heads indicate CRAG inclusions in the nucleus. 
(e) NLS-dependent and GTPase-independent 
NIs of CRAG. HeLa cells expressing HA-CRAG 
of WT, NLS, or GTPase mutants were treated 
with or without a pulse of UV irradiation at 
200 J/m
2. After 2 h, cells were ﬁ  xed and im-
munostained with anti-HA antibody (green) 
and Hoechst 33258 (blue). (f) Spontaneous 
NIs of GFP-CRAG. HeLa cells expressing GFP-
CRAG WT and NLS- and GTPase-deﬁ  cient mu-
tants were stained with Hoechst 33258 (blue). 
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also supported an NLS-dependent NI formation by CRAG (Fig. 
1 f). This suggested that GFP fusion at the NH2 terminus of 
CRAG caused a drastic conformational change in CRAG and 
converted it from an inactive to an active form. An in vitro 
  GTPase assay revealed CRAG activation by UV irradiation and 
spontaneous activation of GFP-CRAG (unpublished data). 
  Collectively, these data demonstrate that CRAG is a unique       
GTPase that forms NI under UV stress in an NLS-dependent 
and GTPase-independent manner, and a conformational change 
in CRAG may induce its intrinsic activity to form NI in an NLS-
dependent manner.
Several nuclear domains have been reported, including 
PML body, a major component of nuclear bodies (Hodges 
et   al., 1998; Lamond and Earnshaw, 1998). Merged images 
demonstrated the colocalization of endogenous CRAG and 
PML bodies with an enlarged ring-like structure in a UV-
stimulated dorsal root ganglion (DRG) neuron (Fig. 2 a and 
Fig. S1 B). Similar results were obtained in UV-stimulated 
HeLa cells expressing HA-CRAG or unstimulated cells ex-
pressing GFP-CRAG. In contrast, HA-CRAG GTPase mu-
tants or GFP-CRAG GTPase mutants did not colocalize with 
PML. Statistical analysis indicated that GTPase activity was 
essential for colocalization of GFP-CRAG with PML. A co-
immunoprecipitation assay demonstrated that endogenous CRAG 
associated with PML in UV-stimulated neurons (Fig. 2   b).
No association of CRAG with PML by antigen peptide against 
anti-CRAG antibody demonstrated the specifi   city of anti-
CRAG antibody. Furthermore, in HeLa cell expression 
Figure 2.  CRAG modulates PML function and 
dynamics. (a) Active CRAG colocalized with 
and induced a large ring-like structure of PML 
body. UV-stimulated DRG neurons were im-
munostained with anti-PML (red), anti-CRAG 
(green), and Hoechst 33258 (blue). HeLa cells 
expressing HA-CRAG WT or GTPase mutants 
were immunostained with anti-PML (green), 
anti-HA (red), and Hoechst 33258 (blue). 
Likewise, unstimulated HeLa cells coexpressing 
HA-PML with GFP-CRAG WT or GTPase mu-
tants were immunostained with anti-HA (red) 
and Hoechst 33258 (blue). Measurement of 
colocalization was performed by counting the 
cells showing colocalization of GFP-CRAG to 
PML on 100 cells. The percentages are cal-
culated from three independent experiments. 
  Error bars represent SD. n = 3.(b) Association 
of endogenous CRAG with PML in response 
to UV stimulation. Lysates of control or UV-
  irradiated hippocampal neurons (100 J/m
2 
for 10 min) were immunoprecipitated with 
anti-CRAG in the presence or absence of 
10 μg/ml antigen peptide against anti-CRAG 
or with anti-PML antibody. Immunoprecipitates 
(IP) were immunoblotted with the indicated 
  antibodies. (c) GFP-CRAG associates with 
PML in a GTPase-dependent manner. Lysates 
or immunoprecipitates with anti-GFP antibody 
from HeLa cells transfected with indicated vec-
tors were immunoblotted with anti-HA (top) or 
anti-GFP antibody (bottom). (d) Colocalization 
of GFP-CRAG WT, but not GTPase mutants, 
with ubiquitin signals. HeLa cells expressing 
GFP-CRAG WT or GTPase mutants were im-
munostained with anti-ubiquitin antibody (red). 
(e) GFP-CRAG induced ubiquitin ligase activity 
in PML immunoprecipitates. Immunoprecipi-
tates of HA-PML WT or HA-PML RING-ﬁ  nger 
(RF) mutants from HeLa cells cotransfected with 
or without GFP-CRAG were used for an in vitro 
ubiquitin ligase assay containing His-tagged 
ubiquitin (described in Materials and meth-
ods) and immunoblotted with the indicated 
antibodies. (f) GFP-CRAG enhanced in vivo 
ubiquitination. Ubiquitinated proteins were im-
munoprecipitated from HeLa cells coexpress-
ing HA-PML and Flag-ubiquitin with or without 
GFP-CRAG and analyzed by immunoblot with 
anti-HA and anti-Flag. Bars, 20 μm.JCB • VOLUME 172 • NUMBER 4 • 2006  500
 system,  GFP-CRAG associated with HA-PML in a GTPase-
dependent manner (Fig. 2 c).
We noticed that ubiquitin signals were accumulated in 
these GFP-CRAG–associated inclusions but not in GTPase mu-
tants (Fig. 2 d). Therefore, we examined whether CRAG stimu-
lated ubiquitin ligase activity in PML immunoprecipitates. An in 
vitro ubiquitin ligase assay revealed that the activity in PML 
  immunoprecipitates was undetectable in the absence of GFP-
CRAG, but GFP-CRAG coexpression induced ubiquitin ligase 
activity in immunoprecipitates of PML WT but not PML RING 
(really interesting new gene)–fi  nger mutants (C51S/C54S; Fig. 
2 e). For in vivo ubiquitination, ubiquitinated proteins were puri-
fi  ed from cells coexpressing HA-PML and Flag ubiquitin with or 
without GFP-CRAG and analyzed by immunoblot with anti-HA 
and anti-Flag antibodies. As shown in Fig. 2 f, ubiquitinated pro-
teins signifi  cantly increased by GFP-CRAG expression. Collec-
tively, these results suggest that CRAG is an inducer for the 
association of unknown ubiquitin ligases with PML or a direct 
activator of PML-associated ubiquitin ligase. Because PML con-
tains a RING-fi  nger domain that confers on it an E3 ubiquitin 
  ligase activity, it is possible that PML is an E3 ubiquitin ligase.
The fact that polyglutamine diseases are characterized 
by the presence of ubiquitinated, PML-associated NIs sug-
gested the possible involvement of CRAG in polyglutamine 
diseases. To ascertain a possible involvement of CRAG in 
polyglutamine diseases, we examined subcellular localization 
of CRAG in the brains of Machado-Joseph disease (MJD) 
  patients and detected specifi   c CRAG inclusion (Fig. 3 a). 
  Similar CRAG inclusions were observed in the brains of 
other MJD patients (unpublished data). To further confi  rm this 
phenomenon, we generated GFP-Q12 as control and GFP-Q69 
as polyQ and examined whether CRAG could interact with 
polyQ. Subcellular distribution analysis revealed the diffuse 
cytoplasmic localization of Q12 and perinuclear aggregation 
of misfolded Q69 in HeLa cells (Fig. 3 b, left). Compared with 
the cytoplasmic distribution of both Q12 and CRAG, Q69 and 
CRAG translocated to the nucleus and formed NIs (Fig. 3 b, 
right). An immunoprecipitation assay also demonstrated that 
CRAG interacted with GFP-Q69 but not -Q12 (Fig. 3, c and e). 
Similarly, in hippocampal neurons expressing GFP-Q69 or 
-Q12, endogenous CRAG associated with GFP-Q69 but not 
-Q12 (Fig. 3 d).
Figure 3.  Association of CRAG with polyQ 
requires ROS generation. (a) Accumulation 
of CRAG NI in the brain of an MJD patient. 
A brain slice (pons) obtained from an MJD 
patient was immunostained with anti-CRAG 
antibody. The arrowhead indicates the NI 
of CRAG. (b) Colocalization of CRAG with 
polyQ in the NIs. HeLa cells expressing GFP-
Q12 or -Q69 are shown as control. HeLa 
cells coexpressing GFP-Q12/HA-CRAG or 
GFP-Q69/HA-CRAG were stained with anti-
HA antibody (red) and Hoechst 33258 (blue). 
(c) Association of CRAG with GFP-Q69 but not 
-Q12. HeLa cells transfected with the indicated 
constructs were immunoprecipitated with anti-
HA antibody (left) or anti-GFP antibody (right) 
and immunoblotted with anti-GFP or anti-HA 
antibodies. (d) Association of endogenous 
CRAG with GFP-Q69 but not -Q12. DRG neu-
ronal cells transfected with the indicated con-
structs were immunoprecipitated with anti-GFP 
antibody and immunoblotted with anti-CRAG 
antibodies and anti-GFP antibodies. (e) ROS 
scavenger blocked Q69-mediated CRAG ac-
tivation. COS-7 cells were transfected with 
the indicated vectors. After 24 h of incuba-
tion with or without ROS scavenger Radicut 
(100 μg/ml), CRAG was immunoprecipitated 
with anti-HA antibody and an in vitro GTPase 
assay was performed. (f) ROS scavenger 
blocked colocalization of CRAG with Q69. 
COS-7 cells were cotransfected with GFP-Q69 
and HA-CRAG in the presence of 100 μg/ml 
Radicut. After 24 h, an immunoﬂ  uorescence 
assay was performed with anti-HA (red) and 
Hoechst 33258 (blue). (g) ROS scavenger 
blocked the interaction of CRAG with GFP-
Q69. COS-7 cells were cotransfected with 
GFP-Q69 and HA-CRAG in the presence of the 
indicated concentration of Radicut. After 24 h, 
CRAG was immunoprecipitated with anti-HA 
and immunoblotted with anti-GFP and anti-HA 
antibodies. Bars, 20 μm.NOVEL NUCLEAR GTPASE CRAG • QIN ET AL. 501
NI formation by CRAG was induced by various stress 
stimuli generating reactive oxygen species (ROS) such as UV. 
Indeed, we found that H2O2 induced CRAG nuclear transloca-
tion and that this was blocked by ROS scavenger edaravone 
(3-methyl-1-phenyl-2-pyrazolin-5-one; Radicut; Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb. 200505079/DC1). 
An in vitro GTPase assay indicated that H2O2 activated CRAG 
GTPase (unpublished data). To understand the mechanism by 
which CRAG recognizes and interacts with polyQ, we focused 
on the role of ROS generation by polyQ in the activation of 
CRAG. An in vitro GTPase assay demonstrated that coexpres-
sion with Q69 but not Q12 activated CRAG GTPase, and this 
activation was blocked by the treatment of ROS scavenger 
Radicut (Fig. 3 e). Actually, Radicut inhibited Q69-mediated 
ROS generation (unpublished data). Furthermore, in Radicut-
treated cells, CRAG failed to colocalize with Q69 and induce 
Q69 nuclear translocation (Fig. 3 f). A coimmunoprecipitation 
assay also indicated that Radicut blocked the association of 
CRAG with Q69 in a Radicut dose–dependent manner (Fig. 
3 g). Thus, ROS may be required for CRAG activation and 
interaction with polyQ.
To confi   rm this, doxycycline (DOX)-inducible Tet-On 
HeLa cell lines expressing HA-CRAG WT and NLS mutants 
were established. Two clones each selected from WT and NLS 
mutants were treated with DOX, and induction of HA-CRAG 
expression was checked by immunoblot analysis using anti-
HA antibody (Fig. 4 a). That equal amount of total protein was 
loaded is shown by tubulin immunoblots (Fig. 4 a, bottom). 
Using these cell systems, we monitored the time-  dependent 
nuclear translocation of Q69 by CRAG. As shown in Fig. 4 b, 
no nuclear localization of Q69 was detected before DOX 
  treatment, but 3 h after DOX treatment, a major part of CRAG 
was colocalized with Q69 aggregates at perinuclear sites and a 
small part of the CRAG–Q69 complex was detected in the NIs. 
Figure 4.  CRAG promotes nuclear transloca-
tion and degradation of polyQ through the 
ubiquitin–proteasome pathway. (a) Establish-
ment of DOX-inducible Tet-On HeLa cell lines 
expressing HA-CRAG WT and NLS mutants. 
Two clones each were treated with or without 
1 μM DOX for 24 h and immunoblotted with 
anti-HA or anti-tubulin antibodies. Cells tran-
siently transfected with control vector, CRAG 
WT, or NLS mutants were indicated in the 
ﬁ   rst two lanes. (b) NLS-dependent nuclear 
translocation of Q69. At 24 h after transient 
transfection of Tet-On HeLa cells with Q69-myc 
(DOX + 0 h), cells were treated with DOX for 
the indicated times and immunostained with 
anti-myc (green), anti-HA antibodies (red), 
and Hoechst 33258 (blue). Merged images 
are shown in insets. (c) Biochemical analysis 
of nuclear translocation of Q69 by CRAG. 
Cytosolic (C) and nuclear (N) fractions from 
HeLa cells transfected with the indicated vec-
tors were separated and immunoblotted with 
anti-HA, anti-myc, and anti–nuclear mitotic 
apparatus protein (NuMA; nuclear marker) 
antibodies. The optical density of Q69 bands 
(bottom) was analyzed by the NIH Image 
  software. (d) Effect of CRAG WT and NLS mu-
tants on the nuclear translocation of Q69. The 
percentage of cells showing nuclear transloca-
tion of Q69 was calculated from 100 HeLa 
cells transfected with the indicated vectors. 
(e) CRAG-dependent disappearance of Q69. 
HA-CRAG–inducible Tet-On HeLa cells were 
transfected with Q69-myc. At 24 h after tran-
sient transfection, cells were treated with or 
without 1 μM DOX for the indicated times and 
immunoblotted with anti-HA, anti-myc, and 
anti-  tubulin antibodies. DOX alone did not af-
fect the Q69 protein level in Tet-On HeLa cells 
without CRAG (WT; right). Note that CRAG ex-
pression did not affect the Q12 protein level. 
(f) MG132 blocked the CRAG-induced Q69 
degradation. COS-7 cells expressing Q69-
myc or Q69-myc/HA-CRAG were treated 
with or without 10 μM MG132 for 6 h and 
immunoblotted with anti-HA and anti-myc an-
tibodies. (g) CRAG suppressed Q69-induced 
cell toxicity. Apoptosis in Tet-On HeLa cells without (left) or with (right) CRAG in the presence or absence of DOX was determined by FACS analysis using 
annexin-V/propidium iodide staining (right). Apoptotic cells were collected in the top right box. (h) GFP-CRAG enhanced in vivo ubiquitination of Q69. 
GFP-Q69 was immunoprecipitated from cells coexpressing GFP-Q69 and Flag-ubiquitin with or without GFP-CRAG and analyzed by immunoblot with the 
indicated antibodies. Bars, 20 μm.JCB • VOLUME 172 • NUMBER 4 • 2006  502
After 6–12 h, almost all CRAG and Q69 translocated to the nu-
cleus and formed NIs. Merged images of CRAG and Q69 (Fig. 
4 b, insets, yellow) demonstrated the colocalization of CRAG 
and Q69 in the nucleus. As a negative control, cells treated with 
solvent for 12 h revealed no nuclear translocation of Q69 (un-
published data). Similar results were obtained in other Tet-On 
HeLa cell lines (unpublished data). On the other hand, NLS 
mutants of CRAG could colocalize with Q69 but not induce 
nuclear translocation of Q69 at all (Fig. 4 b, right). Merged im-
ages (Fig. 4 b, insets, yellow) showed the perinuclear aggregates 
of the CRAG–Q69 complex. Subcellular fractionation analysis 
also indicated CRAG-dependent nuclear translocation of Q69 
and no nuclear localization of Q69 in cells coexpressing NLS 
mutants (Fig. 4 c). Statistical analysis also indicated that CRAG 
WT, but not NLS mutants, induced Q69 nuclear translocation 
(Fig. 4 d). These results demonstrated that CRAG promoted 
Q69 nuclear translocation in an NLS-dependent manner.
The disappearance of polyQ at PML body has been previ-
ously reported as a pathological fi  nding of polyglutamine dis-
eases (Takahashi et al., 2003). We examined CRAG-dependent 
degradation of Q69 using a DOX-inducible Tet-On HeLa cell 
line expressing HA-CRAG. Upon DOX treatment, CRAG ex-
pression was up-regulated, whereas Q69 protein level was con-
comitantly down-regulated. That equal amount of total protein 
was loaded is demonstrated by tubulin immunoblots. A distinct 
background band sometimes appeared as a cross-reacting pro-
tein in the anti-HA immunoblots (Fig. 4 e, left). We confi  rmed 
that DOX alone did not affect Q69 protein level in Tet-On HeLa 
Figure 5.  Knockdown of CRAG in neuronal 
cells blocked nuclear translocation of polyQ 
and polyQ-mediated cell death. (a) Effect of 
siRNA oligonucleotides on CRAG expression 
in COS-7 cells and neurons. Three different 
siRNA oligonucleotides against CRAG se-
quence (411–429, 525–543, and 698–716) 
were synthesized and transfected with HA-
CRAG into COS-7 cells. Scramble oligonucle-
otide (SC) was used as a negative control. 
(left) The arrowhead indicates the position of 
CRAG. SC and siRNA (No. 1) were transfected 
into hippocampal neurons (HN). Inhibitory 
  effect on CRAG expression was estimated by 
immunoblot with the indicated antibodies. The 
optical density of CRAG bands was analyzed 
by the NIH Image software. (b) Knockdown of 
endogenous CRAG by siRNA. Hippocampal 
neurons were ﬁ  xed at 24 h after transfection of 
siRNA (No.1) plus pEGFP vector and immuno-
stained with anti-CRAG antibody (red). Aster-
isks and arrowheads indicate CRAG-deﬁ  cient 
cell body and neurite, respectively. (c) Effect of 
siRNA-mediated CRAG depletion on nuclear 
translocation of Q69. Mouse DRG neurons 
were cotransfected with Q69-myc and scram-
ble or CRAG siRNA. After 24 h of incubation, 
an immunoﬂ  uorescence assay was performed 
with anti-CRAG (red), anti-myc antibodies 
(green), and Hoechst 33258 (blue). Arrows 
and arrowheads indicate CRAG-deﬁ  cient and 
not deﬁ  cient cells, respectively. (d) Knockdown 
of CRAG blocks nuclear translocation of Q69 
and promotes Q69-induced cell death. The 
percentage of cells exhibiting nuclear translo-
cation of Q69 was measured from 100 DRG 
neurons expressing Q69 (top). An immunoﬂ  u-
orescence assay was performed as described 
in panel c and the percentage of cell death 
at 48 h after transfection was measured from 
100 DRG neurons expressing Q69, judged by 
chromatin condensation with Hoechst 33258 
staining (bottom). Error bars represent SD. 
n = 3. (e) Schematic model of CRAG action on 
polyQ. Bars, 20 μm.NOVEL NUCLEAR GTPASE CRAG • QIN ET AL. 503
cells without CRAG (Fig. 4 e, right). As shown in Fig. 4 f, the 
proteasome inhibitor MG132 blocked Q69 down-regulation by 
CRAG WT, suggesting that CRAG may promote Q69 degrada-
tion through the ubiquitin–proteasome pathway. Furthermore, 
FACS analysis of cells stained with annexin-V/propidium io-
dide demonstrated that CRAG WT expression suppressed Q69-
induced cell death (Fig. 4 g). In contrast, DOX alone could not 
rescue Q69-mediated cell death in Tet-On HeLa cells without 
CRAG (Fig. 4 g). To confi  rm ubiquitination of Q69 by CRAG, 
an in vivo ubiquitination assay was performed. As shown in Fig. 
4 h, the ubiquitinated Q69 signifi  cantly increased by CRAG 
  expression. Degradation of Q69 was not enhanced by NLS or 
 GTPase mutants, and DNA ladder formation assays consistently 
revealed that the two mutants could not rescue Q69-mediated 
cell death (unpublished data). Because NLS and GTPase activ-
ity in CRAG are critical for its interaction with PML, CRAG-
mediated activation of PML-associated ubiquitin ligase may be 
responsible for this ubiquitination.
We next examined the effect of CRAG knockdown by 
RNA interference method on nuclear translocation of polyQ 
in neurons. Several small interfering RNA (siRNA) oligonu-
cleotides specifi   cally targeted to the CRAG sequence were 
generated, and their inhibitory effects were estimated using 
the COS-7 cell expression system. All three RNA interference 
 oligonucleotides, but not scramble oligonucleotides, suppressed 
the expression of HA-CRAG (Fig. 5 a, left). Among them, 
one siRNA (No. 1) showing the strongest inhibitory effect on 
CRAG expression was used for the following experiments. This 
siRNA or scramble with Q69 plus pEGFP vector as a marker 
were introduced into cultured rat hippocampal neurons, and 
the inhibitory effect on endogenous CRAG expression was 
evaluated by CRAG immunoblotting and immunostaining. As 
shown in Fig. 5 (a [right] and b) this siRNA, but not scramble, 
was found to suppress endogenous CRAG expression, indicat-
ing that this siRNA against the CRAG gene is useful to assess 
CRAG function.
To determine whether endogenous CRAG is involved in 
nuclear translocation, inclusion body formation, and decreased 
cell toxicity of polyQ in neuronal cells, the effects of CRAG 
knockdown on subcellular distribution and cell toxicity of Q69 
were examined. In scramble siRNA–cotransfected DRG neu-
rons, endogenous CRAG and Q69 translocated to the nucleus 
and formed NIs (Fig. 5 c, top). In contrast, perinuclear aggrega-
tions of Q69 were dominantly detected in siRNA-mediated 
CRAG-defi  cient cells (Fig. 5 c, middle). Moreover, almost all 
CRAG-defi  cient cells revealed a typical apoptotic phenotype 
including chromatin condensation as shown in Fig. 5 c (bottom). 
Statistical analysis indicated that siRNA-mediated CRAG de-
pletion blocked the nuclear translocation of Q69 in DRG neu-
rons (Fig. 5 d, top). In addition, analysis of a cell death assay, 
judging from chromatin condensation, showed that >80% of 
CRAG-defi  cient cells underwent cell death, whereas only 30% 
of scramble siRNA–transfected cells died by Q69 expression 
48 h after transfection (Fig. 5 d, bottom). CRAG knockdown by 
siRNA did not cause death in cells that were not expressing Q69 
(unpublished data). These results demonstrate that endogenous 
CRAG mediates nuclear translocation and NI formation by 
polyQ and confers resistance to cell death under the conditions 
of polyQ accumulation. A schematic model of CRAG action on 
polyQ is shown in Fig. 5 e.
Patients with polyglutamine diseases and transgenic 
mouse model carrying polyQ showed the late-onset and gradu-
ally progressive neurological pathology (Turmaine et al., 2000; 
Katsuno et al., 2003). Indeed, CRAG expression is very high 
in the developing brain and decreased thereafter in the adult 
brain (Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200505079/DC1). This developmentally regulated expres-
sion of CRAG may be closely related to the appearance of poly-
glutamine disease; a decreased level of CRAG expression fails 
to scavenge unfolded proteins at PML bodies and permits an 
accumulation of polyQ aggregates in the nucleus, thereby con-
ferring a toxic gain of function that is selectively deleterious to 
neurons. If so, CRAG is a rate-limiting factor in the degrada-
tion of pathological forms of polyQs and targeted expression of 
CRAG is a potential gene therapy for polyglutamine disease.
Materials and methods
Materials
Anti-Flag M2 monoclonal and anti–α-tubulin antibodies were obtained 
from Sigma-Aldrich. Anti-HA high afﬁ  nity, anti-HA afﬁ  nity matrix, and anti–
c-myc mouse mAbs were obtained from Roche. Anti-GFP rabbit polyclonal 
antibody, annexin V, propidium iodide (PI), and secondary antibodies con-
jugated with Alexa Fluor 488, 594, and 647 were obtained from Invitro-
gen. Anti-6×His monoclonal, anti-GFP mouse monoclonal, and Hoechst 
33258 were obtained from Nacalai Tesque. DOX and mouse MTN blot 
were obtained from CLONTECH Laboratories, Inc. HA-probe was pur-
chased from Santa Cruz Biotechnology, Inc. Nuclear mitotic apparatus 
protein antibody 1 was purchased from Biocarta. Anti-ubiquitin antibody 
was obtained from Santa Cruz Biotechnology, Inc. Anti-HA mouse mAb 
was purchased from Covance. Anti-PML mouse mAb was purchased from 
Santa Cruz Biotechnology, Inc.
Identiﬁ  cation of CRAG in CRAM immunoprecipitates from developing 
rat brain
CRAM (CRMP-5) has been implicated in semaphorin signaling (Inatome 
et al., 2000). We have searched for CRAM-interacting proteins from de-
veloping rat brain. The puriﬁ   cation procedure was performed by using 
anti-CRAM antibody afﬁ  nity column chromatography and speciﬁ  c elution 
with antigen peptides for anti-CRAM antibody. Among puriﬁ  ed proteins, 
we focused on a 42-kD protein, and partial amino acid sequence analysis 
revealed several peptide sequences, including K  S  A  L  V  H  R  Y  L  T  G  T  Y  V  Q  E  E  S  P-
E  G  G  R  F . Based on this information, we cloned a novel gene encoding a 
GTPase from the mouse brain cDNA library (available from GenBank/
EMBL/DDBJ under accession no. AB078345).
Expression constructs
CRAG WT, GTPase mutants, NLS mutants, and murine PML1 isoform (avail-
able from GenBank/EMBL/DDBJ under accession no. BC020990) cDNA 
tagged with the HA epitope at the NH2 terminus were subcloned into pCMV5 
expression vectors. Murine PML1 shows 67% homology to human PML1 at 
the amino acid level. CRAG GTPase mutation was generated by missense 
mutation S114N. CRAG NLS mutation was generated by missense mutation 
KR342-343EE. The plasmid encoding NH2-terminal–truncated ataxin-3 with 
Q69 together with the COOH-terminal myc epitope and the NH2-terminal 
HA epitope was described previously (Yoshizawa et al., 2000). In this plas-
mid, 286 amino acid residues of ataxin-3 were deleted from the NH2-terminal 
side. For our experiment, the HA epitope was removed.
The Q12 gene was created by PCR using the primers 
5′-C  C  C  A  A  G  C  T  T  G  G  G  A  T  G  G  C  C  T  A  C  T  T  T  G  A  A  A  A  A  C  A  G  -3′ and 5′-G  G  G  G  T-
A  C  C  C  C  A  G  G  G  A  A  T  G  A  A  G  A  A  T  A  A  T  G  -3′ and subcloned into pcDNA3.1-
myc His. A RING-ﬁ   nger domain mutation of PML was gener-
ated by the missense mutation C51S/C54S using the PCR primers 
5′-C  C  T  G  C  A  C  A  C  G  C  T  G  A  G  C  T  C  C  G  G  A  A  G  C  C  T  G  G  A  G  G  C  G  C  -3′ and 
5′- G  C  G  C  C  T  C  C  A  G  G  C  T  T  C  C  G  G  A  G  C  T  C  A  G  C  G  T  G  T  G  C  A  G  G  -3′.JCB • VOLUME 172 • NUMBER 4 • 2006  504
Immunoprecipitation, immunoblotting, and immunoﬂ  uorescence 
microscope
These procedures were performed as described previously (Mitsui et al., 
2002; Hotta et al., 2005). Fluorescence images were analyzed on a con-
focal microscope (LSM 510 META; Carl Zeiss MicroImaging, Inc.) equipped 
with three lasers (UV.Ar. 364, Ar. 488, and HeNe 543) using Plan-
  Apochromat 63× oil-immersion (NA 1.40) objective. LSM 510 META 3.0 
software (Carl Zeiss MicroImaging, Inc.) was used for image acquisition 
from confocal microscopy. Photoshop 6.0 software (Adobe) was used for 
minor adjustments to contrast and overlaying.
Immunohistochemistry with pathological specimens
Postmortem brain tissues were obtained from two MJD patients and ana-
lyzed as described previously (Yoshizawa et al., 1990).
GTPase assay for CRAG
The GTPase assay was performed as described previously (Der et al., 1986).
In vitro ubiquitin ligase assay
Immunoprecipitates were washed three times with lysis buffer and once 
with ubiquitination buffer (50 mM Tris-HCL, pH 7.4, 10 mM MgCl2, 5 mM 
ATP, and 2 mM dithiothreitol) and incubated in 50 μl of the same buffer 
supplemented with 100 ng E1 (Honda et al., 1997), 500 ng E2ubcH5(a,b,c) 
(Kobirumaki et al., 2005), and 2.5 μg His-tagged ubiquitin (Calbiochem) 
for 30 min at 25°C. Samples were analyzed with anti-His antibody.
Online supplemental material
Fig. S1 a shows the hollow, doughnut-like nuclear bodies of CRAG in UV-
irradiated hippocampal neurons, and Fig. S1 b shows colocalization of 
CRAG doughnut-like bodies with PML1 in a UV-irradiated DRG neuron. 
Fig. S2 shows NIs of CRAG in response to H2O2 stimulation in HeLa cells. 
Fig. S3 shows a comparison of CRAG expression in adult and developing 
mouse brains. Online supplemental material is available at http://www.
jcb.org/cgi/content/full/jcb.200505079/DC1.
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